Chronic gout can be a relentless and painful condition, particularly for those whose disease has not responded to conventional therapies. Known as chronic refractory gout, this severe form of gout leaves many individuals struggling with debilitating pain, frequent flares, and visible uric acid deposits called tophi. For these patients, Krystexxa (pegloticase) offers a transformative treatment option, providing a unique approach to significantly lower uric acid levels and alleviate the burden of the disease. This comprehensive guide will explore what Krystexxa is, how it works, who can benefit from it, its administration, potential side effects, and what to expect during treatment, empowering you with knowledge about this advanced medication.
Understanding Gout: The Basics
Before diving into Krystexxa, it's essential to understand the underlying condition it treats: gout.
What is Gout?
Gout is a complex and often misunderstood form of inflammatory arthritis. It arises from a metabolic disorder characterized by hyperuricemia, an abnormally high concentration of uric acid in the blood. When uric acid levels consistently exceed the saturation point (typically around 6.8 mg/dL), it can crystallize, forming sharp, needle-like monosodium urate crystals. These crystals then accumulate in joints, tendons, and surrounding tissues, triggering an intense inflammatory response that manifests as acute gout attacks.
Over time, if left untreated or inadequately managed, gout can progress from intermittent acute flares to a chronic, debilitating condition. This chronic phase can lead to persistent pain, joint damage, and the formation of visible, chalky deposits called tophi, which are essentially large accumulations of uric acid crystals in soft tissues and bones.
Symptoms of Gout
The symptoms of gout typically present as sudden, severe attacks, often described as one of the most excruciating forms of pain. While the big toe (podagra) is the most common site, gout can affect any joint. Key symptoms include:
- Acute, Excruciating Joint Pain: The onset is often abrupt, reaching its peak intensity within 4 to 12 hours. Patients frequently describe it as a burning sensation or feeling like the affected joint is being crushed. The pain is so severe that even the slightest touch, such as a bedsheet, can be unbearable.
- Inflammation and Redness: The affected joint becomes markedly swollen, hot to the touch, and appears bright red or purple. This intense inflammatory response is a hallmark of an acute gout flare.
- Tenderness and Swelling: The joint will be extremely tender, making movement or weight-bearing difficult. The swelling can extend beyond the immediate joint.
- Lingering Discomfort: After the most severe pain subsides, which can take several days, a dull ache or discomfort may persist for days or even weeks. The joint may remain sensitive, and movement can be restricted.
- Limited Range of Motion: Chronic gout can lead to progressive joint damage, resulting in stiffness and a reduced ability to fully move the affected joints.
- Tophi: In advanced, chronic cases, visible lumps or nodules called tophi can develop. These firm, painless (unless inflamed) deposits are accumulations of uric acid crystals and can appear on fingers, toes, elbows, ears, or around other joints. Tophi can cause joint deformity, bone erosion, and nerve compression, leading to significant functional impairment.
- Gouty Nephropathy and Kidney Stones: High uric acid levels can also lead to uric acid kidney stones and, in severe cases, chronic kidney disease, further complicating the patient's health.
Causes of Gout
Gout is fundamentally caused by hyperuricemia, an imbalance between uric acid production and excretion. Uric acid is the end product of purine metabolism. Purines are natural compounds found in our cells and in many foods.
Factors contributing to hyperuricemia and gout include:
- Overproduction of Uric Acid: In some individuals, the body produces too much uric acid. This can be due to genetic factors, certain blood disorders, or rapid cell turnover (e.g., in some cancers or during chemotherapy).
- Under-excretion of Uric Acid: More commonly, the kidneys fail to adequately excrete uric acid, leading to its accumulation. This can be influenced by kidney disease, certain medications, or genetic predispositions.
- Dietary Factors: A diet rich in purines significantly contributes to uric acid levels. This includes:
- Red Meat and Organ Meats: Such as liver, kidney, and sweetbreads.
- Certain Seafood: Especially shellfish (shrimp, lobster, crab), anchovies, sardines, and mackerel.
- Alcohol: Particularly beer, which contains purines, and spirits, which can impair uric acid excretion.
- Sugary Drinks and Fructose: High-fructose corn syrup and other sources of fructose can increase uric acid production.
- Obesity and Metabolic Syndrome: Excess body weight is strongly linked to higher uric acid levels and an increased risk of gout. Metabolic syndrome (a cluster of conditions including obesity, high blood pressure, high blood sugar, and abnormal cholesterol levels) is also a significant risk factor.
- Medical Conditions: Untreated hypertension, diabetes, hyperlipidemia, and chronic kidney disease are frequently associated with gout.
- Medications: Certain drugs can elevate uric acid levels, including thiazide and loop diuretics (used for high blood pressure and heart failure), low-dose aspirin, and some immunosuppressants (e.g., cyclosporine).
- Genetics and Family History: A family history of gout increases an individual's susceptibility, indicating a genetic component to uric acid metabolism and excretion.
- Age and Sex: Gout is more prevalent in men, typically developing between the ages of 30 and 50. After menopause, women's risk increases as estrogen levels, which help excrete uric acid, decline.
Diagnosis of Gout
Accurate diagnosis is crucial for effective gout management. The diagnostic process involves:
- Detailed Medical History and Physical Examination: Your doctor will ask about your symptoms, diet, alcohol consumption, medications, and family history. They will examine the affected joints for characteristic signs of inflammation, redness, and swelling, and check for the presence of tophi.
- Blood Tests: Serum uric acid levels are measured. While elevated levels support a diagnosis of gout, it's important to note that uric acid levels can be normal during an acute flare, and many people with hyperuricemia never develop gout. Therefore, blood tests alone are not definitive.
- Joint Fluid Analysis (Arthrocentesis): This is considered the gold standard for diagnosing gout. A sample of fluid is drawn from the inflamed joint and examined under a polarized light microscope for the presence of negatively birefringent monosodium urate crystals. This test can differentiate gout from other forms of arthritis, such as pseudogout.
- Imaging Tests:
- X-rays: Can show joint damage, bone erosions, or tophi in chronic gout, but are often normal in early stages.
- Ultrasound: Increasingly used to detect uric acid crystals in joints, even when not visible on X-rays, and to identify tophi. The 'double contour sign' on ultrasound is highly suggestive of gout.
- Dual-Energy CT (DECT) Scan: This advanced imaging technique can identify and quantify uric acid crystal deposits in joints and soft tissues, even in asymptomatic areas, and is particularly useful for assessing the burden of gout and monitoring treatment effectiveness.
When Standard Treatments Aren't Enough: Chronic Refractory Gout
For the majority of individuals, gout can be effectively managed with a combination of lifestyle modifications and conventional pharmacotherapies. Acute flares are typically treated with nonsteroidal anti-inflammatory drugs (NSAIDs), colchicine, or corticosteroids. Long-term management focuses on lowering uric acid levels using agents such as allopurinol or febuxostat, which reduce uric acid production, or probenecid, which enhances uric acid excretion.
However, a significant challenge arises for patients with chronic refractory gout. This term describes a severe form of the disease where, despite strict adherence to appropriate doses of conventional uric acid-lowering therapies (ULTs), patients:
- Fail to achieve or maintain target serum uric acid levels (typically below 6 mg/dL, or 5 mg/dL for those with tophi).
- Continue to experience frequent and debilitating gout flares (e.g., more than two flares per year).
- Have persistent or worsening tophi, which can lead to significant joint damage, deformity, and functional impairment.
- May have contraindications to, or intolerable side effects from, conventional ULTs.
For these patients, the constant pain, joint destruction, and reduced quality of life significantly impact their daily lives, making a more potent and specialized treatment essential.
Introducing Krystexxa (Pegloticase): The Advanced Solution
Krystexxa steps in as a powerful and unique option for those with chronic refractory gout, offering a mechanism of action distinct from other available treatments.
What is Krystexxa?
Krystexxa is an FDA-approved prescription medication specifically designed for adults with chronic refractory gout. Its active ingredient, pegloticase, is a modified enzyme that belongs to a class of drugs known as biologics. Unlike traditional small-molecule drugs, biologics are complex proteins derived from living organisms, often targeting specific biological pathways.
How Krystexxa Works: The Unique Mechanism of Action
The human body naturally lacks the enzyme uricase, which is responsible for breaking down uric acid into a more soluble compound. This biological deficiency is why humans are susceptible to gout. Krystexxa (pegloticase) effectively bridges this gap with its unique mechanism:
- Enzymatic Conversion: Pegloticase is a recombinant porcine uricase enzyme that has been modified through pegylation. Pegylation involves attaching polyethylene glycol (PEG) molecules to the enzyme, which serves two critical purposes: it extends the enzyme's half-life in the bloodstream, allowing for less frequent dosing, and it helps to reduce the body's immune response against the foreign protein. Once administered, pegloticase directly catalyzes the oxidation of uric acid into allantoin.
- Water-Soluble Allantoin: Allantoin is a harmless, water-soluble substance that is approximately 5 to 10 times more soluble in urine than uric acid. This high solubility ensures that allantoin is readily excreted by the kidneys, effectively removing uric acid from the body.
- Rapid and Sustained Uric Acid Lowering: By actively breaking down uric acid, Krystexxa rapidly and consistently lowers serum uric acid levels, often normalizing them to below the target of 6 mg/dL (and often below 1 mg/dL) within hours of the first infusion. This profound and sustained reduction is crucial for initiating the dissolution of existing uric acid crystals and preventing new ones from forming.
- Tophi Dissolution: The significant and consistent reduction in serum uric acid below the saturation point allows the body to reabsorb and dissolve the uric acid crystals that comprise tophi. This process leads to the shrinkage and even complete disappearance of these debilitating deposits over time, restoring joint architecture and function.
This direct and potent action makes Krystexxa particularly effective for patients with a high burden of uric acid crystals and severe, uncontrolled disease, where other ULTs have failed to achieve adequate crystal dissolution.
Who is Krystexxa For? Indications
Krystexxa is a specialized, potent treatment and is not for everyone with gout. It is specifically indicated for:
- Adult patients diagnosed with chronic gout.
- Patients who have failed to achieve adequate control with conventional oral uric acid-lowering therapies (e.g., allopurinol, febuxostat) at maximum tolerated doses. This includes those who have contraindications to these therapies (e.g., severe renal impairment limiting allopurinol use) or have experienced intolerable side effects from them.
- Individuals who continue to experience frequent and debilitating gout flares (e.g., more than two flares per year), have extensive and persistent tophi, or show evidence of significant joint damage due to gouty arthropathy.
Your rheumatologist or a specialist experienced in gout management will carefully evaluate your medical history, current gout severity, previous treatment responses, and overall health to determine if Krystexxa is the right choice for you.
The Krystexxa Treatment Journey
Receiving Krystexxa involves a specific process designed to maximize its effectiveness and manage potential risks, requiring close collaboration with your healthcare team.
Pre-treatment Screening
Before initiating Krystexxa therapy, your doctor will conduct essential screening tests. The most critical is testing for Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency. G6PD deficiency is a genetic condition that can lead to hemolytic anemia (destruction of red blood cells) when exposed to certain medications, including pegloticase. If you are found to have G6PD deficiency, Krystexxa is generally contraindicated due to this significant risk.
Administration Process
- Intravenous Infusion: Krystexxa is administered as an intravenous (IV) infusion, meaning the medication is delivered directly into your bloodstream through a vein.
- Frequency: Infusions are typically given every two weeks. Consistency in adhering to this schedule is vital for maintaining sustained uric acid lowering.
- Duration: Each infusion usually takes at least two hours to complete. This extended duration allows for slow and controlled delivery of the medication.
- Setting: Due to the potential for significant infusion reactions, Krystexxa must always be administered by a qualified healthcare professional in a supervised medical setting, such as a specialized infusion center, clinic, or hospital. This ensures immediate access to emergency medical equipment and personnel should a reaction occur.
- Pre-medication: To proactively mitigate the risk of infusion reactions, you will almost always receive pre-medications (typically a combination of antihistamines and corticosteroids) approximately 30-60 minutes before each Krystexxa infusion. These medications help to dampen the body's immune response to the foreign protein.
Monitoring During Treatment
Throughout your Krystexxa treatment, your healthcare team will closely monitor your progress and safety:
- Uric Acid Levels: Regular blood tests will be performed, often before each infusion, to monitor your serum uric acid levels. Consistent reduction, typically to below 6 mg/dL (and ideally below 1 mg/dL, which is often achieved with Krystexxa), indicates that the treatment is working effectively. If uric acid levels begin to rise, it may signal the development of anti-drug antibodies, which can affect efficacy.
- Antibody Formation: Your body may develop antibodies against pegloticase over time, leading to a loss of response and an increased risk of infusion reactions. While there isn't a routine test for these antibodies for every infusion, a rising uric acid level often serves as a surrogate marker. Your doctor will monitor for this and may adjust or discontinue treatment if a sustained loss of response is observed.
- Adverse Event Monitoring: You will be closely monitored for any signs or symptoms of adverse reactions, particularly during and immediately after infusions.
Duration of Treatment
The duration of Krystexxa treatment is highly individualized. It is not necessarily a lifelong therapy. Treatment is typically continued until serum uric acid levels are consistently low, tophi have significantly resolved or disappeared, and the clinical signs of gout are substantially improved. Some patients may achieve a durable response and discontinue treatment, while others might require longer courses. Your doctor will regularly assess your response to treatment and determine the appropriate duration based on your specific clinical goals.
Benefits of Krystexxa Treatment
For patients with chronic refractory gout, Krystexxa offers a unique and powerful pathway to significant relief and improved health, often providing benefits not achievable with other therapies.
- Dramatic Uric Acid Reduction: Krystexxa is exceptionally effective at rapidly and consistently lowering serum uric acid levels. Unlike urate-lowering therapies that reduce production or increase excretion, Krystexxa actively metabolizes uric acid, often achieving levels below 1 mg/dL within hours of the first infusion. This rapid and profound reduction is crucial for halting the progression of gout.
- Dissolution of Tophi: One of the most compelling and visible benefits of Krystexxa is its ability to dissolve existing tophi. These unsightly, painful, and often debilitating deposits can shrink or disappear entirely over the course of treatment. This leads to improved joint function, reduced discomfort, and significant cosmetic improvements. The dissolution of tophi can take several months, but it's a clear indicator of the drug's effectiveness.
- Significant Reduction in Gout Flares: By clearing uric acid crystals from the body's tissues and joints, Krystexxa can dramatically decrease the frequency and severity of gout attacks. For patients accustomed to frequent, debilitating flares, this can be a life-changing outcome, restoring predictability and comfort to their lives.
- Improved Joint Function and Reduced Damage: With the dissolution of crystals and sustained reduction of inflammation, patients often experience improved mobility, reduced chronic pain, and a slower progression of joint damage. In some cases, there may even be evidence of bone erosion reversal.
- Enhanced Quality of Life: For individuals who have suffered for years with uncontrolled gout, the alleviation of chronic pain, resolution of tophi, and reduction in flares can profoundly restore their ability to perform daily activities, participate in hobbies, and significantly enhance their overall quality of life and well-being.
- Reduced Risk of Gout-Related Complications: By effectively controlling uric acid levels, Krystexxa can help reduce the long-term risks associated with chronic hyperuricemia, such as kidney damage and the formation of uric acid kidney stones.
Managing Potential Side Effects and Risks
Like all powerful medications, Krystexxa carries potential side effects and risks. It's crucial for patients to be fully informed and for healthcare providers to manage these effectively to ensure patient safety and optimize treatment outcomes.
Infusion Reactions: The Most Common and Critical Concern
Infusion reactions are the most common and potentially serious side effect associated with Krystexxa, occurring in approximately 26% to 30% of patients in clinical trials. These reactions can occur during or within two hours after an infusion, though delayed reactions up to several hours later are also possible. Symptoms can range from mild to severe and may include:
- Mild to Moderate Symptoms: Flushing, hives (urticaria), rash, itching (pruritus), sweating, headache, nausea, dizziness, chest discomfort or pain, shortness of breath, wheezing, throat tightness, or changes in blood pressure (both increases and decreases).
- Severe (Anaphylactoid/Anaphylactic Reactions): These are life-threatening allergic reactions that can include severe difficulty breathing, severe wheezing, swelling of the face, lips, tongue, or throat (angioedema), severe drops in blood pressure (hypotension) leading to shock, rapid heart rate, confusion, or loss of consciousness. While rare, these require immediate medical intervention.
To minimize the risk of infusion reactions, several precautions are taken:
- Supervised Setting: Krystexxa is always administered in a supervised medical setting where medical professionals can closely monitor the patient throughout the infusion and for a period afterward.
- Pre-medication: Patients routinely receive pre-medications (typically a combination of oral or intravenous antihistamines and corticosteroids) approximately 30-60 minutes before each Krystexxa infusion. These help to suppress the immune system's immediate response to the drug.
- Slow Infusion Rate: The infusion is administered slowly over at least two hours to allow for gradual introduction of the medication into the bloodstream.
- Monitoring and Intervention: Healthcare providers are trained to recognize and manage infusion reactions promptly, with emergency medications and equipment readily available.
Other Common Side Effects
Beyond infusion reactions, other side effects reported with Krystexxa include:
- Gout Flares: Paradoxically, as Krystexxa rapidly mobilizes and dissolves existing uric acid crystals from tissues, this process can initially trigger acute gout flares. These are often more common during the first few months of treatment. To manage this, your doctor will typically prescribe anti-inflammatory medications (e.g., NSAIDs, colchicine) to help prevent and manage these initial flares for the first several months.
- Nausea and Vomiting: Gastrointestinal upset is a reported side effect.
- Constipation: Another reported digestive issue.
- Bruising or Redness: At the infusion site, which is common with IV injections.
- Chest Pain: Unrelated to infusion reactions in some cases.
- Upper Respiratory Tract Infections: Some patients may experience an increased incidence of common colds or other respiratory infections.
Important Safety Considerations
- G6PD Deficiency: As previously mentioned, patients with Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency are at a significantly increased risk of hemolytic anemia when treated with Krystexxa. Therefore, screening for G6PD deficiency is mandatory before initiating therapy, and Krystexxa is contraindicated in these individuals.
- Antibody Development and Loss of Response: The body can develop anti-pegloticase antibodies over time. The presence of these antibodies can reduce the drug's effectiveness, leading to a rise in uric acid levels, and significantly increase the likelihood and severity of infusion reactions. Your doctor will monitor your uric acid levels as a surrogate marker for antibody development and may consider discontinuing treatment if a sustained loss of response is observed.
- Not for Asymptomatic Hyperuricemia: Krystexxa is a potent drug with significant risks and is not indicated for individuals with elevated uric acid levels who do not have symptomatic, chronic refractory gout. Its use is reserved for severe, uncontrolled cases.
Living with Gout & Krystexxa
While Krystexxa effectively manages chronic refractory gout, maintaining a healthy lifestyle remains important for overall well-being and to support the treatment's success.
- Dietary Considerations: Continue to adhere to a gout-friendly diet, limiting purine-rich foods (red meat, organ meats, certain seafood), sugary drinks, and excessive alcohol consumption. Focus on a balanced diet rich in fruits, vegetables, whole grains, and lean proteins.
- Hydration: Drink plenty of water throughout the day to help your kidneys efficiently excrete waste products, including allantoin.
- Weight Management: Maintain a healthy body weight through regular exercise and a balanced diet. Losing excess weight can help reduce uric acid levels and decrease the strain on your joints.
- Regular Exercise: Engage in regular, moderate physical activity as advised by your doctor. Exercise can improve joint health, flexibility, and overall cardiovascular well-being.
- Adherence to Treatment: It is crucial to attend all scheduled Krystexxa infusions and diligently follow your doctor's instructions regarding pre-medications and any other prescribed drugs (e.g., for flare prevention). Consistency is key to achieving and maintaining treatment goals.
- Open Communication: Maintain open and honest communication with your healthcare team. Report any new or worsening symptoms, side effects, or concerns promptly.
When to See a Doctor
It is important to consult a healthcare professional in several scenarios:
- For Initial Gout Symptoms: If you experience sudden, severe joint pain, swelling, and redness, especially in the big toe, seek medical attention promptly for an accurate diagnosis and initiation of treatment. Early intervention can prevent chronic complications.
- For Uncontrolled Gout: If your gout symptoms are frequent, debilitating, or not responding adequately to your current medications, or if you have visible lumps under your skin (tophi), it's crucial to discuss these concerns with your doctor. They can assess if your gout is refractory and if advanced treatments like Krystexxa are appropriate.
- During Krystexxa Treatment: Always inform your healthcare provider immediately if you experience any signs of an infusion reaction (e.g., hives, difficulty breathing, chest pain, dizziness, severe headache) during or after an infusion. Also report any new or worsening side effects, persistent gout flares, or any other health concerns.
- For Routine Follow-ups: Regular follow-up appointments with your rheumatologist are essential to monitor your progress, assess uric acid levels, manage side effects, and adjust your treatment plan as needed.
A rheumatologist is the specialist best equipped to diagnose and manage complex gout cases, including determining if Krystexxa is appropriate for you and overseeing your treatment journey.
Frequently Asked Questions (FAQs) About Krystexxa
- What is the primary goal of Krystexxa treatment?
The main goal of Krystexxa is to rapidly and consistently lower serum uric acid levels to below 6 mg/dL (and often below 1 mg/dL) to actively dissolve existing uric acid crystals that form tophi and cause flares. This aims to restore joint function, reduce pain, and significantly improve the quality of life for patients with chronic refractory gout. - How quickly does Krystexxa start working?
Krystexxa typically lowers uric acid levels very rapidly, often within hours of the first infusion. Patients may notice a reduction in the frequency and severity of gout flares after a few months. However, the complete dissolution of tophi and significant improvement in joint damage can take several months to over a year, as the body needs time to clear the dissolved crystals. - Will I still have gout flares while on Krystexxa?
It is common, and even expected, to experience gout flares, especially during the initial months (typically the first 3-6 months) of Krystexxa treatment. This phenomenon occurs because the rapid dissolution of uric acid crystals from tissues can temporarily mobilize them, triggering an inflammatory response. To manage this, your doctor will almost always prescribe concomitant anti-inflammatory medications (e.g., NSAIDs, colchicine) to help prevent and manage these initial flares. - Can I stop my other gout medications when I start Krystexxa?
Your doctor will provide specific instructions regarding your other gout medications. Oral uric acid-lowering therapies (like allopurinol or febuxostat) are typically discontinued before or at the start of Krystexxa therapy, as Krystexxa's mechanism is distinct and potent enough on its own. However, you will likely continue to take anti-inflammatory medications for flare prevention as directed. - What should I do if I experience an infusion reaction?
Since Krystexxa is administered in a supervised medical setting, healthcare professionals will be present to monitor you closely. If you feel any unusual symptoms during or after the infusion (e.g., itching, rash, shortness of breath, dizziness, chest pain), immediately alert your nurse or doctor. They are prepared to manage reactions promptly with emergency medications. - Is Krystexxa a lifelong treatment?
The duration of Krystexxa treatment is highly individualized and is not necessarily a lifelong therapy. Treatment is typically continued until serum uric acid levels are consistently low, tophi have significantly resolved, and the clinical signs of gout are substantially improved. Your doctor will monitor your uric acid levels and clinical response to determine the appropriate duration, which could range from several months to over a year. - Are there alternatives to Krystexxa for refractory gout?
Krystexxa (pegloticase) is currently the only FDA-approved medication that directly converts uric acid to allantoin for the treatment of chronic refractory gout. For patients who cannot tolerate or do not respond to Krystexxa, other strategies may involve optimizing conventional ULTs, using off-label biologics (e.g., IL-1 inhibitors) to manage inflammation, or participating in clinical trials for emerging therapies. However, Krystexxa remains the gold standard for its specific indication. - How expensive is Krystexxa, and is it covered by insurance?
Krystexxa is a high-cost specialty medication. The exact cost varies significantly based on insurance coverage, dosage, and treatment duration. Most patients require assistance navigating insurance claims. Fortunately, the manufacturer often provides patient support programs and financial assistance programs (e.g., co-pay assistance) to help eligible patients afford the medication. Your doctor's office or infusion center can usually help you explore these options.
Conclusion
For individuals grappling with the relentless pain, joint damage, and challenges of chronic refractory gout, Krystexxa (pegloticase) stands as a beacon of hope. By providing a powerful and unique mechanism to rapidly and consistently lower uric acid levels, dissolve debilitating tophi, and significantly reduce gout flares, Krystexxa has transformed the lives of many patients who previously found little relief. While the treatment journey involves intravenous infusions and requires careful monitoring for potential side effects, the profound benefits in terms of pain reduction, improved joint function, and enhanced quality of life often outweigh the risks. If you are struggling with severe, uncontrolled gout, a comprehensive discussion with your rheumatologist about Krystexxa could be the vital step towards reclaiming a more active, comfortable, and fulfilling future.
Sources / Medical References
